WaveMan · Form 4
Bonstein Sara insider trades
> Search tickers & screens ⌘K
LIVE

Bonstein Sara insider trades

Bonstein Sara has filed 39 Form 4s with the SEC that we hold, for INSMED Inc (INSM) (Chief Financial Officer), SCPH (Director) and Xilio Therapeutics, Inc. (XLO) (Director). Across all of them we count 0 purchases worth $0 and 39 sales worth $44.2M reported on Form 4. In the last 12 months: 0 purchases ($0) and 6 sales ($2.1M). The largest single trade was a sale of 220,564 shares of INSMED Inc worth $11.0M, dated 2024-05-29. The first filing on our record is dated 2022-01-10 and the latest 2026-06-12.

INSMED Inc (INSM)

Chief Financial Officer · 29 filings · 39 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-01-11S, sale reported on Form 41,154$29.0K2022-01-13
2022-05-16S, sale reported on Form 41,433$26.5K2022-05-18
2023-01-10S, sale reported on Form 42,857$51.8K2023-01-12
2023-05-15S, sale reported on Form 42,210$42.7K2023-05-17
2023-05-16S, sale reported on Form 41,610$29.7K2023-05-17
2023-12-22S, sale reported on Form 413,199$396.0K2023-12-22
2024-01-09S, sale reported on Form 44,497$131.2K2024-01-11
2024-05-14S, sale reported on Form 411,088$280.7K2024-05-15
2024-05-28S, sale reported on Form 420,724$1.0M2024-05-30
2024-05-29S, sale reported on Form 4220,564$11.0M2024-05-30
2025-01-07S, sale reported on Form 43,470$228.0K2025-01-10
2025-01-08S, sale reported on Form 41,464$96.7K2025-01-10
2025-01-10S, sale reported on Form 41,066$67.9K2025-01-10
2025-02-06S, sale reported on Form 428,390$2.3M2025-02-07
2025-02-11S, sale reported on Form 413,302$1.1M2025-02-13
2025-02-12S, sale reported on Form 45,019$401.5K2025-02-13
2025-02-18S, sale reported on Form 417,622$1.4M2025-02-20
2025-02-18S, sale reported on Form 4700$56.7K2025-02-20
2025-05-13S, sale reported on Form 48,870$601.5K2025-05-15
2025-05-14S, sale reported on Form 41,634$107.2K2025-05-15
2025-06-03S, sale reported on Form 41,579$112.9K2025-06-04
2025-06-10S, sale reported on Form 4100$9.2K2025-06-12
2025-06-10S, sale reported on Form 47,277$634.0K2025-06-12
2025-06-10S, sale reported on Form 47,310$645.4K2025-06-12
2025-06-10S, sale reported on Form 46,328$575.4K2025-06-12
2025-06-10S, sale reported on Form 415,825$1.4M2025-06-12
2025-06-10S, sale reported on Form 420,926$1.9M2025-06-12
2025-06-23S, sale reported on Form 48,661$884.7K2025-06-25
2025-06-23S, sale reported on Form 449,104$5.0M2025-06-25
2025-07-07S, sale reported on Form 422,181$2.1M2025-07-09
2025-07-07S, sale reported on Form 435,583$3.4M2025-07-09
2025-07-21S, sale reported on Form 432,090$3.3M2025-07-23
2025-07-21S, sale reported on Form 426,310$2.7M2025-07-23
2026-01-06S, sale reported on Form 41,517$262.9K2026-01-08
2026-01-07S, sale reported on Form 41,678$293.8K2026-01-08
2026-01-08S, sale reported on Form 41,447$252.0K2026-01-08
2026-02-03S, sale reported on Form 4748$116.9K2026-02-04
2026-05-13S, sale reported on Form 48,272$961.0K2026-05-15
2026-06-03S, sale reported on Form 42,404$245.9K2026-06-05

SCPH

Director · 5 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Xilio Therapeutics, Inc. (XLO)

Director · 5 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1604019) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms